MorphoSys AG
FRANKFURT : MOR

February 23, 2012 09:06 ET

Invitation to Year End 2011 and Q4 Results Conference Call of MorphoSys AG on March 01, 2012

MARTINSRIED / MUNCHEN, GERMANY--(Marketwire - Feb 23, 2012) -

MorphoSys AG / Invitation to Year End 2011 and Q4 Results Conference Call of MorphoSys AG on March 01, 2012 . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will publish its Annual Financial Results 2011 on March 01, 2012 at 7:00 a.m. CET.

The Management team of MorphoSys AG will host a conference call and webcast to present MorphoSys's Annual Financial Results 2011 and provide an outlook for 2012.

DATE: Thursday, March 01, 2012 TIME: 02:00 p.m. CET (01:00 p.m. GMT, 08:00 a.m. EST)

DIAL IN No: +49 (0) 89 2444 329 75 UK RESIDENTS: +44 (0) 20 3003 2666 US RESIDENTS: +1 212 999 6659

Participants of the call are:

Dr. Simon Moroney, Chief Executive Officer Jens Holstein, Chief Financial Officer Dr. Marlies Sproll, Chief Scientific Officer Dr. Arndt Schottelius, Chief Development Officer



We request that you please dial in up to 10 minutes before the call to ensure a prompt start and a secure line.

The presentation slides and webcast link will be available at the Company's website at www.morphosys.com/conference-calls


A slide-synchronized audio replay of the conference will also be available at the corporate website following the live event.




About MorphoSys: MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare. The company's AbD Serotec unit uses HuCAL and other antibody technologies to generate superior monoclonal antibodies for research and diagnostic applications. Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 70 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla® and Ylanthia® are registered trademarks of MorphoSys AG. 100 billion high potentials™ is a trademark of MorphoSys AG.



Conference Alert: http://hugin.info/130295/R/1588479/498521.pdf




This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE

[HUG#1588479]

Contact Information

  • In case of any further questions please contact:

    Dr. Claudia Gutjahr-Loeser
    Head of Corporate Communications & Investor Relations
    Tel: +49 89 899 27-122
    Fax: + 49 89 899 27-5122
    Email Contact

    Mario Brkulj
    Senior Manager Corporate Communications & Investor Relations
    Tel: +49 (0) 89 / 899 27-454
    Fax: +49 (0) 89 / 899 27-5454
    Email Contact

    Jessica Kulpi
    Specialist Corporate Communications & Investor Relations
    Tel: +49 (0) 89 / 899 27-332
    Fax: +49 (0) 89 / 899 27-5332
    Email Contact